Search / Trial NCT00000385

Long-Term Lithium Treatment for Aggressive Conduct Disorder

Launched by DREXEL UNIVERSITY · Nov 2, 1999

Apply for Trial

Trial Information

Current as of June 13, 2024

Completed

Keywords

Aggressive Conduct Disorder Adolescence Child Conduct Disorder Female Lithium Male Placebos Conduct Disorder *Drug Therapy Lithium *Therapeutic Use

Description

Psychotherapeutic agents are often administered without sufficient testing to children and adolescents, often on a long-term basis, to reduce aggression. Many pressures, including managed care, will increase the utilization of pharmacotherapy in the outpatient setting to treat serious problems. Lithium is the most promising agent for the treatment of aggression in children and adolescents. However, it has not been shown that lithium is an effective treatment for these patients in the outpatient (non-hospital) setting, or on a long-term basis. The purpose of this study is to examine the long...

Gender

All

Eligibility criteria

  • Inclusion Criteria:
  • Males and females
  • Ages between 9 and 17 years.
  • Conduct disorder according to DSM-IV (As rated on the DICA-IV).
  • The aggression criterion at screening
  • Exclusion Criteria:
  • Mental Retardation.
  • Pervasive Developmental Disorder(s).
  • Major Depressive Disorder or Dysthymic Disorder.
  • Bipolar Disorder.
  • Psychotic Disorder (including Schizophreniform Disorder and Schizophrenia).
  • Major medical problem such as cardiac, renal, and thyroid diseases, or seizure disorder.
  • History of psychoactive medication in the previous 2 weeks.
  • Current Pregnancy in females.
  • History of Substance Dependence in the past month.
  • Prior to the proposed study, a history of lithium treatment with serum lithium levels of 0.4 mEq/L or higher for a cumulative period of greater than 10 days.

Attachments

readout_NCT00000385_2024-06-13.pdf

4.5 MB

NCT00000385_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Philadelphia, Pennsylvania, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Weekly in short term phase, Monthly in long-term phase

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0